Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Single-Center, Multi-Cohort Phase II Study of Becotatug Vedotin (MRG003) Added to Ongoing Lenvatinib With or Without an Anti-PD-1 Antibody After Progression Following Prior Clinical Benefit in EGFR-Positive Advanced Thyroid Cancer

NCT07874321 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.

NCT NCT07874321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07874321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Single-Center, Multi-Cohort Phase II Study of Becotatug Vedotin (MRG003) Added to Ongoing Lenvatinib With or Without an Anti-PD-1 Antibody After Progression Following Prior Clinical Benefit in EGFR-Positive Advanced Thyroid Cancer
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Phase 2
Overall status
Recruiting
Start date
September 20, 2026
Completion date
December 31, 2027
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced thyroid carcinoma, thyroid cancer, tumor